Colorado doctors and researchers are pioneering advancements that have us closer than ever to finding a cure.
What’s Working: Where a company that develops cancer tests, other startups are finding funding in Colorado
aiGENE is proud to announce to our partnership with the Department of the Air Force Material Command’s competitive awards-based Small Business Innovation Research (SBIR) program
aiGENE has been awarded an Early-Stage Capital and Retention grant through OEDIT’s Advanced Industries Accelerator Program.
AiGene Aims to Remodel Clinical Trials With ctDNA Tech for On-Treatment Response Monitoring (opens PDF) GenomeWeb direct link (requires login)
Dr. Matt Russo from Henry Lab in collaboration with aiGENE presented Electrochemical Biosensor for Point of Care based Monitoring of Cancer Progression using ctDNA Methylscape as a Biomarker
Novel "SMARTer" Clinical Trial Design Improves Odds of Approval and Can Reduce Study Size By Over 80%: Modeling Use of a ctDNA "Optimizing Diagnostic" for Early Therapy Switching in Immuno-Oncology Trials.
Is a hand-held cancer meter feasible?
A simplified, potentially point-of-care (POC), electrode method detects changes in the amount of cfDNA/ctDNA and evaluates the response of advanced cancer patients to therapy
OEDIT Proof of Concept Award
License agreement creates golden opportunity for cancer diagnostic technology